{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:36:53Z","timestamp":1792201013274,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1124\/dmd.112.045237","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:43:57Z","timestamp":1339479837000},"page":"1778-1784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Metabolism of the Active Metabolite of Quetiapine, N-Desalkylquetiapine In Vitro"],"prefix":"10.1016","volume":"40","author":[{"given":"Gry Vibeke","family":"Bakken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Knutsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas","family":"Lunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.045237_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5","volume":"37","author":"Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045237_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":"Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.112.045237_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","article-title":"Fluvoxamine is a potent inhibitor of cytochrome P4501A2","volume":"45","author":"Br\u00f8sen","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.112.045237_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045237_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes","volume":"34","author":"Crewe","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045237_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1124\/dmd.112.045237_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045237_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0920-9964(97)82567-4","article-title":"In vitro prediction of potential metabolic drug interactions for Seroquel (Abstract)","volume":"24","author":"Grimm","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1124\/dmd.112.045237_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","article-title":"In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions","volume":"21","author":"Hasselstr\u00f8m","year":"2006","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/dmd.112.045237_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045237_bib11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/dmd.112.045237_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.104.000125","article-title":"Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations","volume":"32","author":"Jones","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045237_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/dmd.104.002709","article-title":"Metabolism of alfentanil by cytochrome P4503a (cyp3a) enzymes","volume":"33","author":"Klees","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045237_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045237_bib15","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/00912700122012724","article-title":"Human drug metabolism and the cytochromes P450: application and relevance of in vitro models","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045237_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004714-199504000-00008","article-title":"Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants","volume":"15","author":"von Moltke","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.112.045237_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bcp.2003.08.004","article-title":"Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7","volume":"66","author":"Yamaori","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.112.045237_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/abbi.1997.0125","article-title":"Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450\u2013P450 and cytochrome P450\u2013b5 interactions","volume":"342","author":"Yamazaki","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.112.045237_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/prep.2001.1578","article-title":"Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli","volume":"24","author":"Yamazaki","year":"2002","journal-title":"Protein Expr Purif"},{"key":"10.1124\/dmd.112.045237_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/abbi.1996.0022","article-title":"Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes","volume":"325","author":"Yamazaki","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.112.045237_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.045237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:13:00Z","timestamp":1739909580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624227859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090955624227859"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.045237","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism of the Active Metabolite of Quetiapine, N-Desalkylquetiapine In Vitro","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.045237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}